Speaker

With 16 years of deep expertise in the international logistics industry, and 8 years in temperature controlled area. Specializing in the international pharmaceuticals, blood products, and cells transporstion, with comprehensive knowledge of international and domestic import-export regulations.

Dr. Yonghong Zhu is the Chief Medical Officer of EpimAb Biotherapeutics, a bispecific antibody and T cell engager biotech. Dr Zhu’s industry career started in the US, with rising roles from discovery scientist to senior medical director at a few biotechs in the San Francisco Bay Area as well as MNCs including Roche, Genentech, and Takeda. In 2017 he returned to China and served as the Head of Clinical Development at Shanghai Henlius. Later, he became global translational program leader at the Roche Shanghai Innovation Center, focusing on early-stage international clinical research. Prior to joining EpimAb, he was the CMO of Maxinovel Pharmaceuticals. Dr. Zhu completed a 7-year medical program training from Nanjing University Medical School, practiced for a few years, and then received a Ph.D. degree in microbiology & immunology from the University of Rochester School of Medicine & Dentistry. Afterwards he joined an immunology company DNAX (owned by Schering-Plough, later merged into Merck) to complete his industrial postdoctoral training.

Dr. Zhengdan Zhu currently serves as co-president of the drug discovery department at DP Technology, overseeing services and collaborations in early drug discovery and optimization. He earned his Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, followed by joint postdoctoral research at Peking University and the Beijing Institute of Big Data Research. With extensive experience in computer-aided and AI-assisted drug design, Dr. Zhu has published over 30 papers in prestigious international SCI journals, with more than 1,300 citations and an h-index of 19. He also holds several molecular patents as a key contributor. His research interests center on developing innovative strategies to advance drug discovery and molecular optimization from a pragmatic perspective.